MRSN 2.12 (+3.92%)
US59045L1061BiotechnologyBiotechnology

Mersana Therapeutics (MRSN) Stock Highlights

2.12 | +3.92%
2024-09-19 05:08:06
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. The Companys early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Companys Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Companys Immunosynthen platform and target tumor-associated antigens.

Statistics

Range Today
2 2.28
Volume Today 1.17M
Range 1 Year
1.07 6.28
Volume 1 Year 454.95M
Range 3 Year
0.8 10.06
Volume 3 Year 1.54B
Range 10 Year
0.8 29.09
Volume 10 Year 2.09B

Highlights

Market Capitalization 258.84M (small)
Floating Shares 72.29M
Current Price 2.12
Price To Earnings -2.13
Price To Revenue 4.31
Price To Book 30.58
Earnings Per Share -0.85
Payout Ratio 0%

Performance

Latest +3.92%
1 Month +61.83%
3 Months +3.92%
6 Months -57.77%
1 Year +48.25%
3 Years -77.78%
5 Years +17.13%
10 Years -85.36%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.